Free Shipping on Orders Over $75! Ends January 31st.

Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to July 2015

The 2014 World Congress On Insulin Resistance, Diabetes, And Cardiovascular Disease

July 2015

By Ben Best

Metabolic syndrome is a collection of traits that predict both type II diabetes (adult-onset diabetes) and cardiovascular disease. The initial definition of metabolic syndrome, provided by the World Health Organization in 1998, included insulin resistance, elevated blood pressure, abnormal plasma lipids (for example, elevated plasma triglycerides or reduced plasma HDL cholesterol), impaired glucose tolerance, and a high waist-to-hip ratio.1 Many other definitions of metabolic syndrome have been given, with newer ones including markers of chronic inflammation.1 Some scientists challenge the idea that there exists such an entity as “metabolic syndrome.”2,3

The concept of metabolic syndrome was inspired by a 1988 paper by the physician/scientist Gerald Reaven, who described a collection of traits he believed are caused by insulin resistance, and which he said predict cardiovascular disease.4 Dr. Reaven called the collection of traits “Syndrome X.” He did not include obesity or inflammation as traits of Syndrome X.

Insulin resistance was the centerpiece of Syndrome X. Insulin resistance most often refers to the reduced ability of insulin to cause glucose to enter muscle and fat cells, but insulin resistance can also affect the liver, brain, immune system cells, endothelial cells, the beta cells of the pancreas that produce insulin, and other tissues. In 2003, Dr. Reaven co-organized a World Congress on Insulin Resistance. Subsequent conferences have been called the “World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.” From November 20-22, 2014, I attended the 12th Congress in Los Angeles, California.

Central Obesity May Not Always Predict Heart Disease

Reaven
Reaven

Gerald Reaven, MD, (Professor of Medicine, Stanford University) cited studies (particularly from Asian countries) demonstrating that central (abdominal) obesity is not an essential feature for metabolic syndrome, nor for predicting ischemic heart disease5,6 or insulin resistance.7

BMI (Body Mass Index) measures obesity based on the ratio of weight to height (kg/m2). Although BMI has been criticized because it does not distinguish between fat and muscle, possibly because so few people are muscular, BMI has proven to be a convenient measure of obesity in population studies. Dr. Reaven cited studies showing that BMI is equal to or better than waist circumference or wrist-to-hip ratio as a measure of obesity,8 insulin resistance,9 and diabetes.10

When other risk factors are available, such as plasma lipids, blood pressure, and history of diabetes, none of the measures of obesity improve prediction of cardiovascular disease.11 Nonetheless, abdominal obesity is a frequent cause of metabolic syndrome12 and type II diabetes.13

Obesity Treatments

Klein
Klein

Samuel Klein, MD, (Professor of Medicine, Washington University, St. Louis, Missouri) has attempted a variety of interventions to address the problems of obesity, type II diabetes, and metabolic syndrome. Overweight subjects who lost weight through diet and exercise showed a reduction in blood pressure, blood glucose, and blood triglycerides in proportion to the amount of their weight loss.14 Type II diabetics placed on a very calorie-restricted diet (600 calories per day) for eight weeks showed normalization of plasma glucose, liver insulin sensitivity, and insulin production by the pancreas.15

Dr. Klein studied the effect of a low-carbohydrate diet. Although LDL cholesterol leads to atherosclerosis, small LDL particles do so much more than large LDL particles.16 A low-carbohydrate diet reduces blood triglycerides while increasing the size of LDL particles.17 The amount of small LDL particles increase in direct proportion to the percent of carbohydrate in the diet.17 When Dr. Klein put obese patients on a calorie-restricted diet that was either low in fat or low in carbohydrate, both groups lost weight, but the low-carbohydrate group had a greater reduction in triglycerides and blood pressure.18

Abdominal (visceral) fat is associated with chronic inflammation and insulin resistance. Surgical removal of abdominal fat (liposuction) from obese patients had no effect on blood pressure, insulin resistance, plasma glucose, or chronic inflammation.19,20

By contrast, bariatric surgery (surgical procedures to reduce the size of the stomach and/or small intestine) was shown to produce substantial weight loss for at least 10 years. This weight loss was accompanied by improved insulin sensitivity, reduced chronic inflammation, and reversal of factors leading to nonalcoholic fatty liver disease, in addition to reducing death rate.21-24

Gastric bypass is superior to binding methods of bariatric surgery, leading to 25% weight loss after 10 years compared to 16% or less for binding.25 Gastric bypass for type II diabetes more often greatly reduces hemoglobin glycation than sleeve gastronomy.26 Death in the first 30 days after bariatric surgery is rare (0.3%), mostly due to pre-surgical health conditions.27 Complications due to bariatric surgery are largely dependent upon the skillfulness of the surgeon.28 The website of the American Society of Metabolic and Bariatric Surgery (https://asmbs.org) has a search tool for finding a quality local provider of bariatric surgery.

Appetite Suppression With Leptin Hormone

Mantzoros
Mantzoros

Christos Mantzoros, MD, DSc, (Professor of Medicine, Harvard Medical School) is an expert on leptin, the “satiety hormone” that curbs appetite. Leptin is produced by fat cells. Leptin exerts its appetite-satiating effects by acting on the brain, mainly in the hypothalamus. Although blood levels of leptin increase with obesity due to an increase in fat, obese individuals experience less of leptin’s appetite-suppressing effects, a condition known as leptin resistance.29 Leptin administration to obese individuals has not resulted in weight loss.30 A study conducted by Dr. Mantzoros showed that sleep deprivation decreases plasma leptin levels, lending credence to the idea that eating a``t night can make a substantial contribution to obesity.31

Leptin is opposed by ghrelin, a “hunger hormone” that stimulates appetite. Ghrelin is mostly produced by the gut and, like leptin, exerts its effects on appetite by its action on the hypothalamus of the brain. When individuals lose weight, ghrelin blood levels rise. But weight loss due to bariatric surgery greatly reduces ghrelin levels.32

Leptin is only one of several substances released by fat cells, leading to the concept that fat is an endocrine organ.33 Adiponectin, an anti-inflammatory hormone that increases insulin sensitivity, is another major hormone produced by fat cells.33 Pro-inflammatory factors produced by fat cells include TNF-alpha and even leptin, which contribute to the chronic inflammation associated with obesity.34 Nonetheless, leptin is important for brain development, memory formation, protection against age-related brain atrophy, and for removal of the amyloid-beta protein that accumulates in Alzheimer’s disease.35

Artificial Sweeteners Promote Weight Gain

Pepino
Pepino

Yanina Pepino, PhD, (Research Assistant Professor, Washington University School of Medicine, St. Louis, Missouri) studies the effects of artificial sweeteners. The worldwide share of artificial sweeteners is aspartame (27.9%), sucralose (27.9%), cyclamate ( 15.7%), saccharin (13.1%), acesulfame-K (5.2%), and neotame (1.4%).36

In some short-term studies, the use of artificial sweeteners rather than sugar has been shown to slightly reduce weight gain37 or slightly increase weight loss.38 But a 14-year study showed that the consumption of either sugar-sweetened beverages or artificially sweetened beverages was associated with a higher risk of type II diabetes than consumption of fruit juice.39

Similarly, a study lasting seven to eight years found that consumption of artificially sweetened beverages was associated with a nearly 50% greater change in BMI than was seen in non-consumers.40 The authors suggested that subjects prone to weight gain might be more inclined to drink diet beverages. The authors also suggested that artificial sweeteners might increase food intake or increase the appeal of sweetness. Obese subjects given the artificial sweetener sucralose showed increased insulin levels and insulin resistance.41 Insulin levels were also raised in type II diabetics given sucralose and acesulfame-K.42 Mice given the artificial sweeteners aspartame and erythritol showed increased insulin levels and insulin resistance, which was believed to be due to increased plasma triglycerides.43 By contrast, the natural sweetener stevia lowered insulin levels in obese subjects who showed increased insulin following aspartame and sucrose consumption.44

A study of both humans and mice showed that the artificial sweeteners sucralose, aspartame, and saccharin had a substantial effect on gut bacteria that increased glucose intolerance.45 The effect was greater with saccharin than with sucralose or aspartame.

Small
Small

Dana Small, PhD, (Associate Professor of Psychiatry, Yale School of Medicine) has done research on the effects of artificial sweeteners on behavior and the brain. Experiments on rats have shown that appetite results not only from the area of the brain that communicates with hormones (the hypothalamus), but with the area of the brain associated with learning (the hippocampus).46 Dr. Small has shown that this also applies to humans.47 She has shown that learned association occurs between food flavors and the ability of those foods to change blood glucose.48

Rats given foods with artificial sweeteners learn that those foods are not providing calories associated with sweeteners―and compensate by eating more food and becoming obese.49 Mice prefer sucrose over sucralose (which is 600 times sweeter than sucrose) because of an area of the brain that responds to sucrose.50 There is considerable evidence that artificial sweeteners contribute to weight gain in people.51

Calories cause the small intestine to release the hormone glucagon-like peptide 1, which reduces appetite by its effects on the brain. Glucagon-like peptide 1 also increases insulin sensitivity. Rats fed artificial sweetener show reduced glucagon-like peptide 1 secretion and increased food consumption.52 Mice fed the artificial sweetener acesulfame-K showed impaired memory due to disruption of functioning neurons in the hippocampus.53

Vitamin D3 Deficiency Promotes Insulin Resistance

Bernal Mizrachi
Bernal Mizrachi

Carlos Bernal-Mizrachi, MD, (Associate Professor of Cell Biology and Physiology, Washington University, St. Louis, Missouri) has shown that there is a vicious cycle between insulin resistance in the immune system cells (macrophages) that contribute to atherosclerosis and endoplasmic reticulum stress in those cells.54

The endoplasmic reticulum is the organelle in cells that synthesizes proteins, fats, and other macromolecules. By preventing synthesis of vital cell components, endoplasmic reticulum stress disrupts cell function, increases macrophage insulin resistance, and increases atherosclerotic foam cell formation.54

Vitamin D3 deficiency activates endoplasmic reticulum stress in macrophages55,56 and increases blood pressure.57 Persons with low vitamin D levels have higher risk for insulin resistance and metabolic syndrome.58 A review of studies of vitamin D supplementation failed to show prevention of cardiovascular disease, but noted that the dose used in the largest trial was low (400 IU) and had compliance problems.59 A vitamin D3 dose of 2,000 IU daily has been shown to reduce symptoms in patients at risk for diabetes.60 A review of studies showed a direct relationship between vitamin D blood levels and risk of type II diabetes.61

Endothelial Cell Function And Dysfunction

Kearney
Kearney

Mark Kearney, MD, (Professor of Cardiology, University of Leeds, Leeds, UK) has done much research on endothelial dysfunction. The endothelium is the layer of cells covering the walls of blood vessels. Among the most important functions of endothelial cells is to dilate blood vessels by releasing nitric oxide.

Aging and other conditions cause the production of nitric oxide by endothelial cells to decline, a condition described as endothelial dysfunction. Failure of blood vessels to dilate leads to high blood pressure.62 Failure of the coronary arteries of the heart to dilate can lead to a heart attack. For that reason, nitroglycerin tablets (which cause nitric oxide production) are taken to relieve angina and prevent immediate heart attack.63 Increases in free radicals and chronic inflammation associated with aging leads to endothelial dysfunction,64,65 which contributes to atherosclerosis.66 Smoking leads to endothelial dysfunction, which can be somewhat reversed by smoking cessation.67

Dr. Kearney’s team has established that insulin resistance in endothelial cells leads to endothelial dysfunction,68 a result that has been confirmed by others.69 His team has shown that reducing free radicals reduces endothelial dysfunction.

Insulin resistance in the endothelial cells precedes insulin resistance in the liver and muscles.70 Dr. Kearney noted that endothelial dysfunction is highly associated with metabolic syndrome.71 Type II diabetes has the effect of 15 years of additional aging on blood vessels.72 An estimated 25% of chronic heart failure patients have type II diabetes.73

Lipoprotein(a) As A Cardiovascular Disease Risk Factor

Tsimikas
Tsimikas

Sotirios Tsimikas, MD, (Director of Vascular Medicine, San Diego Health Center) is concerned with the effect of lipoprotein(a) on cardiovascular disease risk. Lipoprotein(a) is a special kind of LDL particle that can cause atherosclerosis independently of other LDL particles.74,75

Lipoprotein(a) consists of an LDL particle that is bound to the glycoprotein (sugared-protein) apoprotein(a).76 Some genetic variants of lipoprotein(a) are associated with greater cardiovascular risk than others.77 Lipoprotein(a) binds strongly both to the proteoglycans in blood vessel walls and to oxidized phospholipids.78-80

Niacin has been reported to slightly reduce plasma lipoprotein(a),81,82 but niacin has not been shown to reduce cardiovascular events in patients receiving statin theapy.83 The most effective therapy is apheresis (removal of lipoprotein(a) by filtering the blood). Apheresis that reduced LDL-cholesterol by 65% and lipoprotein(a) by 73% reduced major cardiac events by 86%, a result that cannot be explained by the LDL reduction alone.78

Metabolic Syndrome Factors

Ferrannini
Ferrannini

Ele Ferrannini, MD, (Professor of Internal Medicine, University of Pisa, Pisa, Italy) studies correlation of factors associated with metabolic syndrome. In one study, Dr. Ferrannini showed that there is a direct association between insulin resistance and endothelial function in patients with type II diabetes.84 The same study found insulin resistance in type II diabetes to be associated with chronic inflammation and with an impaired ability to prevent blood clots (impaired fibrinolysis), even in persons who were not obese.84

As obesity increases, fat cells become larger, and larger fat cells become more insulin resistant. As abdominal obesity increases, glucose uptake is reduced in both skeletal muscle and fat.85 Other studies by Dr. Ferrannini showed that insulin resistance increases in direct proportion to waist circumference86 and blood pressure.87 Glucose tolerance measures how rapidly glucose is reduced in the bloodstream after being administered. A person has poor glucose tolerance if glucose is not rapidly reduced. Dr. Ferrannini showed that impaired glucose tolerance is directly related to insulin resistance of the insulin-producing beta cells of the pancreas.88

Atherosclerosis In Childhood

Raitakari
Raitakari

Olli Raitakari, MD, PhD, (Professor of Cardiovascular Medicine, University of Turku, Turku, Finland) began his talk by referring to the fact that more than three-quarters of American soldiers killed and autopsied in the Korean War (with an average age of 22) had gross signs of atherosclerosis.89

Dr. Raitakari has found that children with risk factors for cardiovascular disease (based on lipids and blood pressure) typically will develop atherosclerosis as adults.90

Based on his research, screening children for atherosclerosis (thickness in the intima-media of blood vessels) beginning at the age of 9 could identify children who would most benefit from therapies to prevent cardiovascular disease.91 Dr. Raitakari has found that obese children who become nonobese as adults have a similar cardiovascular risk as those who were never obese.92 He also found that having both parents smoke had the effect of increasing blood vessel age by an average of 3.3 years.93

Cancer Due To Obesity And Diabetes

LeRoith
LeRoith

Derek LeRoith, MD, PhD, (Director of Diabetes Research, Rambam Health Care Campus, Haifa, Israel) studies the effect of obesity and diabetes on cancer. In the US, cancer deaths due to overweight and obesity are estimated to be 14% for men and 20% for women.94

Cancer cells avidly consume glucose, and insulin is a growth factor that enhances cancer growth (many cancer cells have insulin receptors).95 People with insulin resistance, such as type II diabetics, and people with metabolic syndrome have high blood plasma levels of both glucose and insulin, which accelerates cancer growth.95 Women without diabetes who have had surgery for early-stage breast cancer have a greatly increased risk of cancer recurrence if their plasma insulin levels are high.96

Type II diabetics show a steady decline in insulin production by their pancreas such that after 10 years, half of these diabetics require insulin injections.97 Diabetics receiving insulin or insulin analogs have an increased risk of cancer in proportion to the size of the dose of insulin or insulin analog.98

But type II diabetics receiving metformin have reduced plasma glucose and insulin, which reduces their incidence of cancer.99 By one estimate, the overall reduction in cancer risk with metformin is 31%.100 Gastric bypass surgery of severely obese subjects has reduced cancer risk by 60%.101

Diabetic Neuropathy

Jacobs
Jacobs

Allen Jacobs, Doctor of Podiatric Medicine, (private practice, St. Louis, Missouri) is concerned with medical conditions resulting from high blood glucose of persons with type II diabetes, especially with the condition of neuropathy.

Neuropathy is damage to nerves, which impairs sensation, movement, and other functions.

Diabetic neuropathy is present in 8% of newly diagnosed type II diabetics, and in over 40% of diabetics who have had the disease for more than 10 years.102 Diabetic neuropathy is the major cause of kidney disease, and is the most common cause of blindness in middle-aged adults.103 More than half of all foot amputations are due to diabetes.104

The antidiabetic drug metformin lowers blood levels of vitamin B12, which may worsen neuropathy.105 Oral administration of vitamin B12 in the form of Methyl-B12 (methylcobalamin) has been shown to relieve symptoms of diabetic neuropathy.106

Obesity And Alzheimer’s Disease

Craft
Craft

Suzanne Craft, PhD, (Professor of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina) is concerned about metabolic syndrome and the risk of dementia, especially Alzheimer’s disease.

Above the age of 40, obesity is associated with a reduction of gray matter (neurons) in the brain.107 A study of non-demented elderly found that high insulin levels were associated with subsequent higher incidence of Alzheimer’s disease.108 High insulin levels in the elderly are associated with less gray matter in the areas of the brain most associated with Alzheimer’s disease,109 and is associated with reduced metabolic rate in those areas.110

Mouse experiments indicate that insulin deficiency or insulin resistance can increase aggregation of the amyloid-beta,111 or tau112 proteins associated with Alzheimer’s disease. Conversely, insulin has been shown to reduce amyloid-beta binding and protect synapses.113,114 Dr. Craft has shown that moderate doses of insulin improved cognitive function in adults with mild cognitive impairment or mild-to-moderate Alzheimer’s disease.115 Higher or lower doses of insulin did not improve cognitive function.

Conclusions

The annual Southern California World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease has much in common with the annual South Florida Cardiovascular Disease Prevention Symposium, described in the July 2014 issue of Life Extension® magazine. Both are conferences that attract several hundred people, where most of the presenters are MDs. These physicians do not discuss disease without discussing both prevention and treatment. The Congress has a greater emphasis on insulin resistance, diabetes, and obesity, but cardiovascular disease is the major cause of death for these conditions.

Some key points in this Congress include the substantial beneficial effects that bariatric surgery can have for reducing obesity and the health consequences of obesity; artificial sweeteners lead to weight gain, rather than weight loss; and that obesity and metabolic syndrome can lead to not only diabetes and cardiovascular disease but cancer, neuropathy, and Alzheimer’s disease.

If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.

References

  1. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162.
  2. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005 Sep;28(9):2289-304.
  3. Grundy SM. Does the metabolic syndrome exist? Diabetes Care. 2006 Jul;29(7):1689-92; discussion 1693-6.
  4. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988 Dec;37(12):1595-607.
  5. Lee J, Ma S, Heng D, Tan CE, Chew SK, Hughes K, Tai ES. Should central obesity be an optional or essential component of the metabolic syndrome? Ischemic heart disease risk in the Singapore Cardiovascular Cohort Study. Diabetes Care. 2007 Feb;30(2):343-7.
  6. Ninomiya JK, L’Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004 Jan 6;109(1):42-6.
  7. Palaniappan LP, Kwan AC, Abbasi F, Lamendola C, McLaughlin TL, Reaven GM. Lipoprotein abnormalities are associated with insulin resistance in South Asian Indian women. Metabolism. 2007 Jul;56(7):899-904.
  8. Taylor AE, Ebrahim S, Ben-Shlomo Y, et al. Comparison of the associations of body mass index and measures of central adiposity and fat mass with coronary heart disease, diabetes, and all-cause mortality: a study using data from 4 UK cohorts. Am J Clin Nutr. 2010 Mar;91(3):547-56.
  9. Abbasi F, Malhotra D, Mathur A, Reaven GM, Molina CR. Body mass index and waist circumference associate to a comparable degree with insulin resistance and related metabolic abnormalities in South Asian women and men. Diab Vasc Dis Res. 2012 Oct;9(4):296-300.
  10. Balkau B, Lange C, Fezeu L, Tichet J, de Lauzon-Guillain B, Czernichow S, Fumeron F, Froguel P, Vaxillaire M, Cauchi S, Ducimetière P, Eschwège E. Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care. 2008 Oct;31(10):2056-61.
  11. Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, Di Angelantonio E, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011 Mar 26;377(9771):1085-95.
  12. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2010 Jan 16;375(9710):181-3.
  13. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013 Jan;93(1):359-404.
  14. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type II diabetes. Diabetes Care. 2011 Jul;34(7):1481-6.
  15. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type II diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011 Oct;54(10):2506-14.
  16. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002 Sep;43(9):1363-79.
  17. Krauss RM, Blanche PJ, Rawlings RS, Fernstrom HS, Williams PT. Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia. Am J Clin Nutr. 2006 May;83(5):1025-31.
  18. Foster GD, Wyatt HR, Hill JO, et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med. 2010 Aug 3;153(3):147-57.
  19. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004 Jun 17;350(25):2549-57.
  20. Fabbrini E, Tamboli RA, Magkos F, et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology. 2010 Aug;139(2):448-55.
  21. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012 Jan 4;307(1):56-65.
  22. Bradley D, Conte C, Mittendorfer B, et al. Gastric bypass and banding equally improve insulin sensitivity and β cell function. J Clin Invest. 2012 Dec;122(12):4667-74.
  23. Klein S, Mittendorfer B, Eagon JC, et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology. 2006 May;130(6):1564-72.
  24. Arterburn DE, Olsen MK, Smith VA, et al. Association between bariatric surgery and long-term survival. JAMA. 2015 Jan 6;313(1):62-70.
  25. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007 Aug 23;357(8):741-52.
  26. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med. 2014 May 22;370(21):2002-13.
  27. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium, Flum DR, Belle SH, et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009 Jul 30;361(5):445-54.
  28. Birkmeyer JD, Finks JF, O’Reilly A, et al. Surgical skill and complication rates after bariatric surgery. N Engl J Med. 2013 Oct 10;369(15):1434-42.
  29. Pan H, Guo J, Su Z. Advances in understanding the interrelations between leptin resistance and obesity. Physiol Behav. 2014 May 10;130:157-69.
  30. Moon HS, Dalamaga M, Kim SY, et al. Leptin’s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev. 2013 Jun;34(3):377-412.
  31. Mullington JM, Chan JL, Van Dongen HP, et al. Sleep loss reduces diurnal rhythm amplitude of leptin in healthy men. J Neuroendocrinol. 2003 Sep;15(9):851-4.
  32. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002 May 23;346(21):1623-30.
  33. Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism. 2015 Jan;64(1):131-45.
  34. Procaccini C, Pucino V, Mantzoros CS, Matarese G. Leptin in autoimmune diseases. Metabolism. 2015 Jan;64(1):92-104.
  35. Farr OM, Tsoukas MA, Mantzoros CS. Leptin and the brain: influences on brain development, cognitive functioning and psychiatric disorders. Metabolism. 2015 Jan;64(1):114-30.
  36. Schiffman SS. Rationale for further medical and health research on high-potency sweeteners. Chem Senses. 2012 Oct;37(8):671-9.
  37. De Ruyter JC, Olthof MR, Seidell JC, Katan MB. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med. 2012 Oct 11;367(15):1397-406.
  38. Tate DF, Turner-McGrievy G, Lyons E, et al. Replacing caloric beverages with water or diet beverages for weight loss in adults: main results of the Choose Healthy Options Consciously Everyday (CHOICE) randomized clinical trial. Am J Clin Nutr. 2012 Mar;95(3):555-63.
  39. Fagherazzi G, Vilier A, Saes Sartorelli D, Lajous M, Balkau B, Clavel-Chapelon F. Consumption of artificially and sugar-sweetened beverages and incident type II diabetes in the Etude Epidemiologique aupres des femmes de la Mutuelle Generale de l’Education Nationale-European Prospective Investigation into Cancer and Nutrition cohort. Am J Clin Nutr. 2013 Mar;97(3):517-23.
  40. Fowler SP, Williams K, Resendez RG, Hunt KJ, Hazuda HP, Stern MP. Fueling the obesity epidemic? Artificially sweetened beverage use and long-term weight gain. Obesity (Silver Spring). 2008 Aug;16(8):1894-900.
  41. Pepino MY, Tiemann CD, Patterson BW, Wice BM, Klein S. Sucralose affects glycemic and hormonal responses to an oral glucose load. Diabetes Care. 2013 Sep;36(9):2530-5.
  42. Brown RJ, Walter M, Rother KI. Effects of diet soda on gut hormones in youths with diabetes. Diabetes Care. 2012 May;35(5):959-64.
  43. Mitsutomi K, Masaki T, Shimasaki T, Gotoh K, Chiba S, Kakuma T, Shibata H. Effects of a nonnutritive sweetener on body adiposity and energy metabolism in mice with diet-induced obesity. Metabolism. 2014 Jan;63(1):69-78.
  44. Anton SD, Martin CK, Han H, et al. Effects of stevia, aspartame, and sucrose on food intake, satiety, and postprandial glucose and insulin levels. Appetite. 2010 Aug;55(1):37-43.
  45. Suez J, Korem T, Zeevi D, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014 Oct 9;514(7521):181-6.
  46. Davidson TL, Chan K, Jarrard LE, Kanoski SE, Clegg DJ, Benoit SC. Contributions of the hippocampus and medial prefrontal cortex to energy and body weight regulation. Hippocampus. 2009 Mar;19(3):235-52.
  47. Rudenga KJ, Small DM. Amygdala response to sucrose consumption is inversely related to artificial sweetener use. Appetite. 2012 Apr;58(2):504-7.
  48. De Araujo IE, Lin T, Veldhuizen MG, Small DM. Metabolic regulation of brain response to food cues. Curr Biol. 2013 May 20;23(10):878-83.
  49. Swithers SE, Davidson TL. A role for sweet taste: calorie predictive relations in energy regulation by rats. Behav Neurosci. 2008 Feb;122(1):161-73.
  50. García-Cáceres C, Tschöp MH. The emerging neurobiology of calorie addiction. Elife. 2014;3:e01928.
  51. Yang Q. Gain weight by “going diet?” Artificial sweeteners and the neurobiology of sugar cravings: Neuroscience 2010. Yale J Biol Med. 2010 Jun;83(2):101-8.
  52. Swithers SE, Laboy AF, Clark K, Cooper S, Davidson TL. Experience with the high-intensity sweetener saccharin impairs glucose homeostasis and GLP-1 release in rats. Behav Brain Res. 2012 Jul 15;233(1):1-14.
  53. Cong WN, Wang R, Cai H, et al. Long-term artificial sweetener acesulfame potassium treatment alters neurometabolic functions in C57BL/6J mice. PLoS One. 2013 Aug 7;8(8):e70257.
  54. Oh J, Riek AE, Weng S, et al. Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation. J Biol Chem. 2012 Apr 6;287(15):11629-41.
  55. Riek AE, Oh J, Sprague JE, et al. Vitamin D suppression of endoplasmic reticulum stress promotes an antiatherogenic monocyte/macrophage phenotype in type II diabetic patients. J Biol Chem. 2012 Nov 9;287(46):38482-94.
  56. Riek AE, Oh J, Bernal-Mizrachi C. 1,25(OH)2 vitamin D suppresses macrophage migration and reverses atherogenic cholesterol metabolism in type II diabetic patients. J Steroid Biochem Mol Biol. 2013 Jul;136:309-12.
  57. Weng S, Sprague JE, Oh J, Riek AE, Chin K, Garcia M, Bernal-Mizrachi C. Vitamin D deficiency induces high blood pressure and accelerates atherosclerosis in mice. PLoS One. 2013;8(1):e54625.
  58. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004 May;79(5):820-5.
  59. Pittas AG, Chung M, Trikalinos T, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010 Mar 2;152(5):307-14.
  60. Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr. 2011 Aug;94(2):486-94.
  61. Song Y, Wang L, Pittas AG, Del Gobbo LC, Zhang C, Manson JE, Hu FB. Blood 25-hydroxy vitamin D levels and incident type II diabetes: a meta-analysis of prospective studies. Diabetes Care. 2013 May;36(5):1422-8.
  62. Taddei S, Virdis A, Ghiadoni L, Salvetti G, Bernini G, Magagna A, Salvetti A. Age-related reduction of NO availability and oxidative stress in humans. Hypertension. 2001 Aug;38(2):274-9.
  63. Ferreira JC, Mochly-Rosen D. Nitroglycerin use in myocardial infarction patients. Circ J. 2012;76(1):15-21.
  64. McCann SM, Mastronardi C, de Laurentiis A, Rettori V. The nitric oxide theory of aging revisited. Ann N Y Acad Sci. 2005 Dec;1057:64-84.
  65. Donato AJ, Morgan RG, Walker AE, Lesniewski LA. Cellular and molecular biology of aging endothelial cells. J Mol Cell Cardiol. 2015 Feb 2. pii: S0022-2828(15)00034-6.
  66. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):168-75.
  67. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):509-15.
  68. Duncan ER, Crossey PA, Walker S, et al. Effect of endothelium-specific insulin resistance on endothelial function in vivo. Diabetes. 2008 Dec;57(12):3307-14.
  69. Wu G, Meininger CJ. Nitric oxide and vascular insulin resistance. Biofactors. 2009 Jan-Feb;35(1):21-7.
  70. Kim F, Pham M, Maloney E, et al. Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):1982-8.
  71. Cubbon RM, Mercer BN, Sengupta A, Kearney MT. Importance of insulin resistance to vascular repair and regeneration. Free Radic Biol Med. 2013 Jul;60:246-63.
  72. Cubbon R, Kahn M, Kearney MT. Secondary prevention of cardiovascular disease in type II diabetes and prediabetes: a cardiologist’s perspective. Int J Clin Pract. 2008 Feb;62(2):287-99.
  73. Cubbon RM, Adams B, Rajwani A, et al. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diab Vasc Dis Res. 2013 Jul;10(4):330-6.
  74. Nestel PJ, Barnes EH, Tonkin AM, et al. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler Thromb Vasc Biol. 2013 Dec;33(12):2902-8.
  75. Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014 Feb 11;129(6):635-42.
  76. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009 Jun 10;301(22):2331-9.
  77. Thanassoulis G, et.al. CHARGE Extracoronary Calcium Working Group. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013 Feb 7;368(6):503-12.
  78. Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med. 2013 Jan;273(1):6-30.
  79. Leibundgut G, Scipione C, Yin H, et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res. 2013 Oct;54(10):2815-30.
  80. Tsimikas S, Clopton P, Brilakis ES, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation. 2009 Apr 7;119(13):1711-9.
  81. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010 Dec;31(23):2844-53.
  82. Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism. 2013 Apr;62(4):479-91.
  83. Albers JJ, Slee A, O’Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013 Oct 22;62(17):1575-9.
  84. Natali A, Toschi E, Baldeweg S, et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type II diabetes. Diabetes. 2006 Apr;55(4):1133-40.
  85. Virtanen KA, Iozzo P, Hällsten K, et al. Increased fat mass compensates for insulin resistance in abdominal obesity and type II diabetes: a positron-emitting tomography study. Diabetes. 2005 Sep;54(9):2720-6.
  86. Ferrannini E, Balkau B, Coppack SW, et al. Insulin resistance, insulin response, and obesity as indicators of metabolic risk. J Clin Endocrinol Metab. 2007 Aug;92(8):2885-92.
  87. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Järvinen H. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension. 1997 Nov;30(5):1144-9.
  88. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2005 Jan;90(1):493-500.
  89. Enos WF Jr, Beyer JC, Holmes RH. Pathogenesis of coronary disease in American soldiers killed in Korea. J Am Med Assoc. 1955 Jul 16;158(11):912-4.
  90. Raitakari OT, Juonala M, Kähönen M, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA. 2003 Nov 5;290(17):2277-83.
  91. Juonala M, Magnussen CG, Venn A, et al. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Mus catine Study for the International Childhood Cardiovascular Cohort (i3C) Consorti um. Circulation. 2010 Dec 14;122(24):2514-20.
  92. Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med. 2011 Nov 17;365(20):1876-85.
  93. Gall S, Huynh QL, Magnussen CG, et al. Exposure to parental smoking in childhood or adolescence is associated with increased carotid intima-media thickness in young adults:evidence from the Cardiovascular Risk in Young Finns study and the Childhood Determinants of Adult Health Study. Eur Heart J. 2014 Sep 21;35(36):2484-91.
  94. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003 Apr 24;348(17):1625-38.
  95. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer:translational challenges. J Mol Endocrinol. 2012 Mar 29;48(3):R31-43.
  96. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002 Jan 1;20(1):42-51.
  97. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995 Nov;44(11):1249-58. Erratum in: Diabetes 1996 Nov;45(11):1655.
  98. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009 Sep;52(9):1732-44.
  99. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type II diabetes. Diabetologia. 2009 Sep;52(9):1766-77.
  100. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010 Nov;3(11):1451-61.
  101. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007 Aug 23;357(8):753-61.
  102. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995 Jul 13;333(2):89-94.
  103. Sheetz MJ, King GL. Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA. 2002 Nov 27;288(20):2579-88.
  104. Leone S, Pascale R, Vitale M, Esposito S. Epidemiology of diabetic foot. Infez Med. 2012;20 Suppl 1:8-13.
  105. Wile DJ, Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care. 2010 Jan;33(1):156-61.
  106. Miranda-Massari JR, Gonzalez MJ, Jimenez FJ, Allende-Vigo MZ, Duconge J. Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control. Curr Clin Pharmacol. 2011 Nov;6(4):260-73.
  107. Willette AA, Kapogiannis D. Does the brain shrink as the waist expands? Ageing Res Rev. 2015 Mar;20C:86-97.
  108. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 2004 Oct 12;63(7):1187-92.
  109. Willette AA, Xu G, Johnson SC, et al Insulin resistance, brain atrophy, and cognitive performance in late middle-aged adults. Diabetes Care. 2013 Feb;36(2):443-9.
  110. Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type II diabetes. Arch Neurol. 2011 Jan;68(1):51-7.
  111. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB J. 2004 May;18(7):902-4.
  112. Planel E, Tatebayashi Y, Miyasaka T, et al. Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci. 2007 Dec 12;27(50):13635-48. PubMed PMID: 18077675.
  113. Zhao WQ, Lacor PN, Chen H, et al. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}.J Biol Chem. 2009 Jul 10;284(28):18742-53.
  114. De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1971-6.
  115. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012 Jan;69(1):29-38.